Radium Ra-223
- Generic Name
- Radium Ra-223
- Drug Type
- Small Molecule
- Chemical Formula
- Ra
- CAS Number
- 15623-45-7
- Unique Ingredient Identifier
- 8BR2SOL3L1
- Background
Radium 223 is under investigation in clinical trial NCT02463799 (Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC).
PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- Drug: Other standard care
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1434
- Registration Number
- NCT04256993
- Locations
- 🇸🇪
Database Study, Database Study, Sweden
Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone
- Conditions
- Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 194
- Registration Number
- NCT04232761
- Locations
- 🇨🇳
Many locations, Multiple Locations, Taiwan
Radium-223 in Biochemically Recurrent Prostate Cancer
- Conditions
- Biochemical Recurrent Prostate Cancer
- Interventions
- Drug: 18F Sodium Fluoride
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT04206319
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 39
- Registration Number
- NCT04109729
- Locations
- 🇺🇸
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States
RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers
- Conditions
- Prostate Cancer
- Interventions
- Radiation: stereotactic ablative radiotherapy (SABR)
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2024-11-04
- Target Recruit Count
- 64
- Registration Number
- NCT04037358
- Locations
- 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2019-06-24
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 8
- Registration Number
- NCT03996473
- Locations
- 🇺🇸
Ccare San Marcos Cancer Center & Urology, San Marcos, California, United States
🇳🇱Nederlands Kanker Instituut, Amsterdam, Netherlands
🇧🇪UZ Gent, Gent, Belgium
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 346
- Registration Number
- NCT03896984
- Locations
- 🇺🇸
US Flatiron prostate cancer database, Whippany, New Jersey, United States
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 738
- Registration Number
- NCT03574571
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Yale University- Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Helen Graham Cancer Center (Christiana Care), Newark, Delaware, United States
A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2020-05-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 164
- Registration Number
- NCT03563014
- Locations
- 🇧🇪
Many Locations, Multiple Locations, Belgium
Treatment Satisfaction With Ra-223 in Japan
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 85
- Registration Number
- NCT03315260
- Locations
- 🇯🇵
Many Locations, Multiple Locations, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.